Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens.

BACKGROUND

Neurocognitive disorders due to human immunodeficiency virus (HIV) remain highly prevalent, specifically mild forms despite effective antiretroviral therapy (ART). Dolutegravir-based regimens are the first line of treatment for adult HIV-positive patients. Controversies exist regarding the neurocognitive effects of dolutegravir. Evidence regarding the neurocognitive effects of dolutegravir is important, in support of its use in patients with HIV-associated neurocognitive disorders (HAND).

AIM

This study aimed to describe the change in cognitive function using the International HIV Dementia Scale (IHDS) and Brief Neuropsychological Cognitive Examination (BNCE) in HIV positive, treatment naïve patients before and 3 months after initiation of ART using a dolutegravir-based regimen.

SETTING

The HIV initiation clinic of Hillbrow Community Health Centre in Johannesburg.

METHODS

This prospective, quantitative cohort study assessed adult HIV-positive patients who were ART naïve being initiated on a dolutegravir-based regimen, using the BNCE and IHDS at baseline and after 3 months of treatment.

RESULTS

Neurocognitive test results of 26 participants showed significant improvements for IHDS ( = 1.84, = 0.033) and time to complete BNCE ( = 2.47, = 0.007). BNCE total results showed improvements that were not significant ( = 1.44, = 0.075); however, Part 2 of the BNCE reflecting that of executive function showed significant improvements ( = 66.5, = 0.043).

CONCLUSION

The trend of neurocognitive function is towards improvement in HIV-positive treatment naïve patients who receive 3 months of dolutegravir-based ART.

CONTRIBUTION

The findings support the use of dolutegravir-based regimens in the treatment of patients with HIV-associated neurocognitive disorders.

KEYWORDS

HIV-associated neurocognitive disorders; BNCE; IHDS; dolutegravir; neurocognitive screening; neurocognitive impairment; South Africa.